Enhanced diacylglycerol production by phospholipase D activation is responsible for abnormal increase in concanavalin A cap formation in polymorphonuclear leukocytes from Chediak-Higashi syndrome (beige) mice
- PMID: 24830864
- DOI: 10.1016/j.intimp.2014.05.003
Enhanced diacylglycerol production by phospholipase D activation is responsible for abnormal increase in concanavalin A cap formation in polymorphonuclear leukocytes from Chediak-Higashi syndrome (beige) mice
Abstract
We previously reported that enhanced ceramide production induces calpain-mediated proteolysis of protein kinase C (PKC) in leukocytes from Chediak-Higashi syndrome (CHS). In the present study, we demonstrated that phospholipase D (PLD) inhibitors ameliorated abnormal increases in concanavalin A (Con A) cap formation in polymorphonuclear leukocytes (PMNs) from beige mouse, an animal model of CHS. PLD activity in PMNs from beige mice enhanced at 30 to 60s after Con A stimulation. In Con A-stimulated beige PMNs, both neutral sphingomyelinase (N-SMase) and acidic sphingomyelinase (A-SMase) activities enhanced, and ceramide levels are also increased. We found that ceramide levels were reversed by the treatment of beige PMNs with propranolol which inhibits phosphatidic acid phosphohydrolase. In addition, we showed that diacylgycerol (DAG) analogs enhance both N-SMase and A-SMase activities in PMNs from normal mice. We subsequently examined the association of CHS1 with PLD, and showed that expression of a truncated mutant of CHS1 in 293T cells induced abnormally rapid activation of PLD after phorbol ester stimulation. Moreover, we showed that specific inhibitors of 14-3-3 proteins, which interact with CHS1/LYST and bind PKC, did not affect abnormal increases in Con A cap formation in beige PMNs. These results suggest that the enhanced DAG production via the PLD pathway is associated with abnormal increases in Con A cap formation in beige PMNs, and that CHS1 may be involved in the regulation of PLD activity.
Keywords: CHS1/LYST; Calpain; Ceramide; Chediak–Higashi syndrome; Phospholipase D; Protein kinase C.
Copyright © 2014 Elsevier B.V. All rights reserved.
Similar articles
-
A thiol proteinase inhibitor, E-64-d, corrects the abnormalities in concanavalin A cap formation and the lysosomal enzyme activity in leucocytes from patients with Chediak-Higashi syndrome by reversing the down-regulated protein kinase C activity.Clin Exp Immunol. 2001 Aug;125(2):283-90. doi: 10.1046/j.1365-2249.2001.01598.x. Clin Exp Immunol. 2001. PMID: 11529921 Free PMC article.
-
Effect of a thiol proteinase inhibitor, E-64-d, on susceptibility to infection with Staphylococcus aureus in Chediak-Higashi syndrome (beige) mice.Int Immunopharmacol. 2007 Jul;7(7):973-80. doi: 10.1016/j.intimp.2007.03.004. Epub 2007 Apr 16. Int Immunopharmacol. 2007. PMID: 17499200
-
Thiol proteinase inhibitors reverse the increased protein kinase C down-regulation and concanavalin A cap formation in polymorphonuclear leukocytes from Chediak-Higashi syndrome (beige) mouse.J Leukoc Biol. 1990 Nov;48(5):377-81. doi: 10.1002/jlb.48.5.377. J Leukoc Biol. 1990. PMID: 2230592
-
Chediak-Higashi syndrome.Curr Opin Hematol. 2008 Jan;15(1):22-9. doi: 10.1097/MOH.0b013e3282f2bcce. Curr Opin Hematol. 2008. PMID: 18043242 Review.
-
Impaired microtubule function correctable by cyclic GMP and cholinergic agonists in the Chediak-Higashi syndrome.Am J Pathol. 1976 Nov;85(2):395-418. Am J Pathol. 1976. PMID: 187062 Free PMC article. Review.
Cited by
-
Towards the targeted management of Chediak-Higashi syndrome.Orphanet J Rare Dis. 2014 Aug 18;9:132. doi: 10.1186/s13023-014-0132-6. Orphanet J Rare Dis. 2014. PMID: 25129365 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous